Clinical Trials Browser

Terminated × Docetaxel × 90 days × Clear all

NCT05062980 2026-06-03

Acclaim-2

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Terminated

190 enrolled 13 charts

Breast Neoplasms

NCT04154956 2026-05-18

CARMEN-LC03

Phase 3 Terminated

389 enrolled 16 charts

Non-small Cell Lung Cancer Metastatic

NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

Phase 2 Terminated

15 enrolled 11 charts

Prostatic Neoplasms

NCT03337698 2026-05-12

Morpheus Lung

Phase 1/2 Terminated

314 enrolled 31 charts

Carcinoma, Non-Small-Cell Lung

NCT02257619 2026-04-21

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05567835 2026-04-09

TOGAR

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

Head and Neck Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients